Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long term survival in three pancreatic cancer patients following Whipple's procedure and allogeneic hematopoietic cell transplantation.

Frontiers in immunology·2026

Same author

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

American journal of hematology·2026

Same author

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

The Lancet regional health. Europe·2026

Same author

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026

Same author

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Individualized pharmacotherapy with paclitaxel.

Stephan Mielke¹

¹Department of Hematology and Oncology, University Medical Center, Freiburg, Germany. mielkes@nhlbi.nih.gov

Current Opinion in Oncology

|October 2, 2007

Summary

Paclitaxel chemotherapy response and toxicity can be personalized. Understanding patient factors like genetics and drug metabolism helps tailor treatment for better outcomes and safety.

Area of Science:

Pharmacology
Oncology
Genetics

Background:

Paclitaxel is a vital anticancer drug with over 20 years of clinical use.
Interindividual pharmacokinetic variability and population modeling offer new avenues for optimizing paclitaxel therapy.
Patient safety and treatment efficacy are continuously being improved through advanced research.

Purpose of the Study:

To review demographic, pharmacokinetic, and genetic factors influencing paclitaxel efficacy and toxicity.
To explore the potential for individualizing paclitaxel treatment strategies.
To discuss the translation of research findings into clinical practice.

Main Methods:

Analysis of existing clinical data and pharmacokinetic studies.
Investigation of demographic factors (age, gender, bilirubin levels).

More Related Videos

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Related Experiment Videos

Last Updated: Jul 11, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Examination of genetic polymorphisms in drug-metabolizing enzymes and transporters (e.g., CYP450, P-glycoprotein, OATP1B3).

Main Results:

Age, gender, and bilirubin levels impact paclitaxel pharmacokinetics.
Paclitaxel exposure thresholds predict neutropenia, neuropathy, and survival.
Genetic variations, particularly in ABCB1 and CYP3A4, are linked to paclitaxel-related toxicity and pharmacokinetics.

Conclusions:

Demographic, pharmacokinetic, and genetic factors significantly influence paclitaxel treatment outcomes.
Individualized therapeutic approaches based on these covariables are feasible.
Translating these findings into bedside applications can enhance patient care and treatment effectiveness.